A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2018
At a glance
- Drugs Ribociclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 01 Jan 2018 Results assessing maximum tolerated dose and recommended dose for expansion, published in the Cancer Science.
- 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
- 01 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.